UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

X QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 28, 2015

OR

TRANSITION REPORT PURSUANT TO SECTION 13

OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______ to _______

COMMISSION FILE NUMBER 1-3619

----

PFIZER INC.

(Exact name of registrant as specified in its charter)

DELAWARE

(State of Incorporation)

13-5315170

(I.R.S. Employer Identification No.)

235 East 42nd Street, New York, New York 10017

(Address of principal executive offices) (zip code)

(212) 733-2323

(Registrant s telephone number)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.

YES X

NO ___

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T ( 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

YES X

NO ___

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act (check one):

Large Accelerated filer X Accelerated filer ___ Non-accelerated filer ___ Smaller reporting company ___

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

YES ____

NO X

At August 3, 2015, 6,167,347,758 shares of the issuer s voting common stock were outstanding.

Table of Contents

PART I. FINANCIAL INFORMATION

Page

Item 1.

Financial Statements

Condensed Consolidated Statements of Income for the three and six months ended June 28, 2015 and June 29, 2014

Condensed Consolidated Statements of Comprehensive Income for the three and six months ended June 28, 2015 and

June 29, 2014

Condensed Consolidated Balance Sheets as of June 28, 2015 and December 31, 2014

Condensed Consolidated Statements of Cash Flows for the three and six months ended June 28, 2015 and June 29, 2014

Notes to Condensed Consolidated Financial Statements

Review Report of Independent Registered Public Accounting Firm

37

Item 2.

Management s Discussion and Analysis of Financial Condition and Results of Operations

38

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

85

Item 4.

Controls and Procedures

85

PART II. OTHER INFORMATION

Item 1.

Legal Proceedings

86

Item 1A.

Risk Factors

86

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

87

Item 3.

Defaults Upon Senior Securities

87

Item 4.

Mine Safety Disclosures

87

Item 5.

Other Information

87

Item 6.

Exhibits

88

Signature

89

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(UNAUDITED)

Three Months Ended

Six Months Ended

(MILLIONS, EXCEPT PER COMMON SHARE DATA)

June 28,

2015

June 29,

2014

June 28,

2015

June 29,

2014

Revenues

11,853

12,773

22,717

24,126

Costs and expenses:

Cost of sales(a)

2,180

2,462

4,018

4,507

Selling, informational and administrative expenses(a)

3,386

3,520

6,491

6,560

Research and development expenses(a)

1,734

1,759

3,620

3,382

Amortization of intangible assets

872

1,001

1,811

2,118

Restructuring charges and certain acquisition-related costs

86

81

146

139

Other (income)/deductions net

55

(53

570

Income from continuing operations before provision for taxes on income

3,539

4,003

6,621

6,850

Provision for taxes on income

905

1,082

1,610

1,664

Income from continuing operations

2,635

2,921

5,011

5,186

Discontinued operations net of tax

73

Net income before allocation to noncontrolling interests

2,635

2,921

5,017

5,259

Less: Net income attributable to noncontrolling interests

14

18

Net income attributable to Pfizer Inc.

2,626

2,912

5,002

5,241

Earnings per common share basic:

Income from continuing operations attributable to Pfizer Inc. common shareholders

0.43

0.46

0.81

0.81

Discontinued operations net of tax

0.01

Net income attributable to Pfizer Inc. common shareholders

0.43

0.46

0.81

0.82

Earnings per common share diluted:

Income from continuing operations attributable to Pfizer Inc. common shareholders

0.42

0.45

0.80

0.80

Discontinued operations net of tax

0.01

Net income attributable to Pfizer Inc. common shareholders

0.42

0.45

0.80

0.81

Weighted-average shares basic

6,159

6,368

6,181

6,379

Weighted-average shares diluted

6,243

6,444

6,267

6,460

Cash dividends paid per common share

0.28

0.26

0.56

0.52

(a)

Excludes amortization of intangible assets, except as disclosed in Note 9A. Identifiable Intangible Assets and Goodwill:Identifiable Intangible Assets.

Amounts may not add due to rounding.

See Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(UNAUDITED)

Three Months Ended

Six Months Ended

(MILLIONS OF DOLLARS)

June 28,

2015

June 29,

2014

June 28,

2015

June 29,

2014

Net income before allocation to noncontrolling interests

2,635

2,921

5,017

5,259

Foreign currency translation adjustments, net

(327

233

(1,635

158

Reclassification adjustments(a)

(62

(327

233

(1,635

96

Unrealized holding gains/(losses) on derivative financial instruments, net

452

137

(57

Reclassification adjustments for realized (gains)/losses(b)

(743

74

(510

86

(291

75

(373

29

Unrealized holding gains/(losses) on available-for-sale securities, net

(200

(15

(527

93

Reclassification adjustments for realized (gains)/losses(b)

498

(79

745

(178

299

(94

218

(85

Benefit plans: actuarial gains/(losses), net

(9

(11

22

(5

Reclassification adjustments related to amortization(c)

134

49

269

98

Reclassification adjustments related to settlements, net(c)

22

18

62

39

Other

(29

(9

130

(26

118

47

483

106

Benefit plans: prior service credits and other, net

507

506

Reclassification adjustments related to amortization(c)

(34

(18

(69

(36

Reclassification adjustments related to curtailments, net(c)

(7

15

(17

11

Other

(2

(2

(1

464

(3

418

(26

Other comprehensive income/(loss), before tax

263

258

(890

120

Tax provision/(benefit) on other comprehensive income/(loss)(d)

228

332

(12

Other comprehensive income/(loss) before allocation to noncontrolling interests

35

253

(1,222

132

Comprehensive income before allocation to noncontrolling interests

2,670

3,174

3,795

5,391

Less: Comprehensive income/(loss) attributable to noncontrolling interests

24

(3

31

Comprehensive income attributable to Pfizer Inc.

2,663

3,150

3,797

5,360

(a)

Reclassified into Discontinued operations net of tax in the condensed consolidated statements of income.

(b)

Reclassified into Other (income)/deductions net in the condensed consolidated statements of income.

(c)

Generally reclassified, as part of net periodic pension cost, into Cost of sales, Selling, informational and administrative expenses, and/or Research and development expenses, as appropriate, in the condensed consolidated statements of income. For additional information, see Note 10. Pension and Postretirement Benefit Plans.

(d)

See Note 5C. Tax Matters: Tax Provision/(Benefit) on Other Comprehensive Income/(Loss).

Amounts may not add due to rounding.

See Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(MILLIONS OF DOLLARS)

June 28,

2015

December 31,

2014

(Unaudited)

Assets

Cash and cash equivalents

3,670

3,343

Short-term investments

26,586

32,779

Trade accounts receivable, less allowance for doubtful accounts: 2015 $397; 2014 $412

8,951

8,401

Inventories

5,796

5,663

Current deferred tax assets and other current tax assets

4,263

4,498

Other current assets

2,449

3,019

Total current assets

51,715

57,702

Long-term investments

17,650

17,518

Property, plant and equipment, less accumulated depreciation

11,432

11,762

Identifiable intangible assets, less accumulated amortization

33,424

35,166

Goodwill

41,571

42,069

Noncurrent deferred tax assets and other noncurrent tax assets

1,450

1,544

Other noncurrent assets

3,635

3,513

Total assets

160,878

169,274

Liabilities and Equity

Short-term borrowings, including current portion of long-term debt

8,394

5,141

Trade accounts payable

2,930

3,210

Dividends payable

1,726

1,711

Income taxes payable

1,057

531

Accrued compensation and related items

1,646

1,841

Other current liabilities

8,390

9,197

Total current liabilities

24,143

21,631

Long-term debt

26,729

31,541

Pension benefit obligations, net

6,529

7,885

Postretirement benefit obligations, net

1,969

2,379

Noncurrent deferred tax liabilities

24,659

24,981

Other taxes payable

4,359

4,353

Other noncurrent liabilities

5,310

4,883

Total liabilities

93,698

97,652

Preferred stock

28

29

Common stock

458

455

Additional paid-in capital

80,407

78,977

Treasury stock

(79,098

(73,021

Retained earnings

73,620

72,176

Accumulated other comprehensive loss

(8,521

(7,316

Total Pfizer Inc. shareholders equity

66,894

71,301

Equity attributable to noncontrolling interests

286

321

Total equity

67,180

71,622

Total liabilities and equity

160,878

169,274

Amounts may not add due to rounding.

See Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

Six Months Ended

(MILLIONS OF DOLLARS)

June 28,

2015

June 29,

2014

Operating Activities

Net income before allocation to noncontrolling interests

5,017

5,259

Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:

Depreciation and amortization

2,461

2,880

Asset write-offs and impairments

42

189

Adjustment to gain on disposal of discontinued operations

(66

Deferred taxes from continuing operations

(183

853

Deferred taxes from discontinued operations

(2

Share-based compensation expense

347

281

Benefit plan contributions in excess of expense

(842

(124

Other adjustments, net

(194

(299

Other changes in assets and liabilities, net of acquisitions and divestitures

(1,873

(1,949

Net cash provided by operating activities

4,775

7,022

Investing Activities

Purchases of property, plant and equipment

(497

(570

Purchases of short-term investments

(16,029

(21,081

Proceeds from redemptions/sales of short-term investments

20,483

20,795

Net proceeds from redemptions/sales of short-term investments with original maturities of 90 days or less

3,020

1,399

Purchases of long-term investments

(5,422

(5,327

Proceeds from redemptions/sales of long-term investments

3,291

2,947

Acquisitions of businesses, net of cash acquired

(679

Acquisitions of intangible assets

(12

(56

Other investing activities, net

333

288

Net cash provided by/(used in) investing activities

4,487

(1,605

Financing Activities

Proceeds from short-term borrowings

2,022

Principal payments on short-term borrowings

(10

(7

Net proceeds from/(payments on) short-term borrowings with original maturities of 90 days or less

481

(2,692

Proceeds from issuance of long-term debt

4,491

Principal payments on long-term debt

(3,002

(752

Purchases of common stock

(6,000

(2,520

Cash dividends paid

(3,483

(3,320

Proceeds from exercise of stock options

981

583

Other financing activities, net

154

43

Net cash used in financing activities

(8,857

(4,173

Effect of exchange-rate changes on cash and cash equivalents

(78

(21

Net increase in cash and cash equivalents

327

1,223

Cash and cash equivalents, beginning

3,343

2,183

Cash and cash equivalents, end

3,670

3,406

Supplemental Cash Flow Information

Cash paid during the period for:

Income taxes

1,124

1,068

Interest

914

996

Amounts may not add due to rounding.

See Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 1. Basis of Presentation and Significant Accounting Policies

A. Basis of Presentation

We prepared the condensed consolidated financial statements following the requirements of the United States (U.S.) Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by accounting principles generally accepted in the United States of America (U.S. GAAP) can be condensed or omitted.

Balance sheet amounts and operating results for subsidiaries operating outside the U.S. are as of and for the three and six months ended May 24, 2015 and May 25, 2014.

In the condensed consolidated balance sheet as of December 31, 2014, we performed certain reclassifications to conform to current period presentation, none of which were material to our financial statements.

Unless the context requires otherwise, references to Pfizer, the Company, we, us or our in this Quarterly Report on Form 10-Q refer to Pfizer Inc. and its subsidiaries.

On February 5, 2015, we announced that we entered into a definitive merger agreement under which we agreed to acquire Hospira, Inc. (Hospira), the world s leading provider of injectable drugs and infusion technologies and a global leader in biosimilars, for $90 per share in cash, for a total enterprise value of approximately $17 billion. We expect to finance the transaction through a combination of existing cash and new debt, with approximately two-thirds of the value financed from cash and one-third from debt. The transaction is subject to customary closing conditions, including regulatory approvals in several jurisdictions, and is expected to close in the second half of 2015. On May 13, 2015, Hospira shareholders voted in favor of the proposal to adopt the merger agreement, which was also a condition to closing the transaction. On August 4, 2015, the European Commission approved the transaction under the European Union (EU) Merger Regulation. The European Commission s decision includes our commitment to divest certain assets in the EU.

Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.

We are responsible for the unaudited financial statements included in this Quarterly Report on Form 10-Q. The financial statements include all normal and recurring adjustments that are considered necessary for the fair presentation of our condensed consolidated balance sheets and condensed consolidated statements of income.

The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our 2014 Annual Report on Form 10-K.

Certain amounts in the condensed consolidated financial statements and associated notes may not add due to rounding. All percentages have been calculated using unrounded amounts.

B. Adoption of New Accounting Standard

We adopted a new accounting and disclosure standard as of January 1, 2015 that limits the presentation of discontinued operations to when the disposal of the business operation represents a strategic shift that has had or will have a major effect on our operations and financial results. This new standard is applied prospectively to all disposals (or classifications as held for sale) of components of an entity that occur within annual periods beginning on or after December 15, 2014, and interim periods within those years. We did not have any disposals within the scope of this new standard and, therefore, there were no impacts to our condensed consolidated financial statements.

C. Fair Value

Our fair value methodologies depend on the following types of inputs:

Quoted prices for identical assets or liabilities in active markets (Level 1 inputs).

Quoted prices for similar assets or liabilities in active markets or quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than quoted prices that are directly or indirectly observable, or inputs that are derived principally from, or corroborated by, observable market data by correlation or other means (Level 2 inputs).

Unobservable inputs that reflect estimates and assumptions (Level 3 inputs).

A single estimate of fair value can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 2. Acquisition, Collaborative Arrangements, Equity-Method Investment and Cost-Method Investment

A. Acquisition

Marketed Vaccines Business of Baxter International Inc. (Baxter)

On December 1, 2014 (which falls in the first fiscal quarter of 2015 for our international operations), we completed the acquisition of Baxter s portfolio of marketed vaccines for a final purchase price of $648 million. The portfolio that was acquired consists of NeisVac-C and FSME-IMMUN/TicoVac. NeisVac-C is a vaccine that helps protect against meningitis caused by group C meningococcal meningitis and FSME-IMMUN/TicoVac is a vaccine that helps protect against tick-borne encephalitis. In connection with this acquisition, we recorded $376 million in Identifiable intangible assets, primarily consisting of $371 million in Developed technology rights. We also recorded $194 million of Inventories and $12 million in Goodwill. The final allocation of the consideration transferred to the assets acquired and the liabilities assumed has been completed.

B. Collaborative Arrangements

Collaboration with Eli Lilly & Company (Lilly)

In October 2013, we entered into a collaboration agreement with Lilly to jointly develop and globally commercialize Pfizer s tanezumab, which provides that Pfizer and Lilly will equally share product-development expenses as well as potential revenues and certain product-related costs. On March 23, 2015, Pfizer and Lilly announced that the companies are preparing to resume the Phase 3 clinical program for tanezumab. As a result, on March 27, 2015, we received a $200 million upfront payment from Lilly in accordance with the collaboration agreement between Pfizer and Lilly, which is recorded as deferred income in our condensed consolidated balance sheet and is being recognized into Other (income)/deductions net over a multi-year period beginning in the second quarter of 2015. This announcement followed a decision by the U.S. Food and Drug Administration (FDA) to lift the partial clinical hold on the tanezumab development program after a review of nonclinical data characterizing the sympathetic nervous system response to tanezumab. Under the collaboration agreement with Lilly, we are eligible to receive additional payments from Lilly upon the achievement of specified regulatory and commercial milestones.

Collaboration with OPKO Health, Inc. (OPKO)

On December 13, 2014, we entered into a collaborative agreement with OPKO to develop and commercialize OPKO s long-acting human growth hormone (hGH-CTP) for the treatment of growth hormone deficiency (GHD) in adults and children, as well as for the treatment of growth failure in children born small for gestational age (SGA) who fail to show catch-up growth by two years of age. hGH-CTP has the potential to reduce the required dosing frequency of human growth hormone to a single weekly injection from the current standard of one injection per day. We have received the exclusive license to commercialize hGH-CTP worldwide. OPKO will lead the clinical activities and will be responsible for funding the development programs for the key indications, which include Adult and Pediatric GHD and Pediatric SGA. We will be responsible for all development costs for additional indications, all postmarketing studies, manufacturing and commercialization activities for all indications, and we will lead the manufacturing activities related to product development. The transaction closed on January 28, 2015, upon termination of the waiting period under the Hart-Scott-Rodino Act. In February 2015, we made an upfront payment of $295 million to OPKO, which was recorded in Research and development expenses, and OPKO is eligible to receive up to an additional $275 million upon the achievement of certain regulatory milestones. OPKO is also eligible to receive royalty payments associated with the commercialization of hGH-CTP for Adult GHD, which is subject to regulatory approval. Upon the launch of hGH-CTP for Pediatric GHD, which is subject to regulatory approval, the royalties will transition to tiered gross profit sharing for both hGH-CTP and our product, Genotropin.

C. Equity-Method Investment

Investment in ViiV Healthcare Limited (ViiV)

Our minority ownership interest in ViiV, a company formed in 2009 by Pfizer and GlaxoSmithKline plc (GSK) to focus solely on research, development and commercialization of human immunodeficiency virus (HIV) medicines, was impacted by the January 21, 2014 European Commission approval of Tivicay (dolutegravir), a product for the treatment of HIV-1 infection, developed by ViiV. This approval triggered a reduction in our equity interest in ViiV from 12.6% to 11.7%, effective April 1, 2014. As a result, in the first six months of 2014, we recognized a loss of approximately $28 million in Other (income)/deductions net.

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

D. Cost-Method Investment

AM-Pharma B.V. (AM-Pharma)

On April 9, 2015, we acquired a minority equity interest in AM-Pharma, a privately held Dutch biopharmaceutical company focused on the development of recombinant human Alkaline Phosphatase (recAP) for inflammatory diseases, and secured an exclusive option to acquire the remaining equity in the company. The option becomes exercisable upon delivery of the clinical trial report after completion of a Phase II trial of recAP in the treatment of Acute Kidney Injury related to sepsis. Results from the current Phase II trial for recAP are expected in the second half of 2016. Under the terms of the agreement, we paid $87.5 million for both the exclusive option and the minority equity interest, which was recorded as a cost-method investment in Long-term investments, and we may make additional payments of up to $512.5 million upon exercise of the option and potential launch of any product that may result from this investment.

Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives

We incur significant costs in connection with acquiring, integrating and restructuring businesses and in connection with our global cost-reduction/productivity initiatives. For example:

In connection with acquisition activity, we typically incur costs associated with executing the transactions, integrating the acquired operations (which may include expenditures for consulting and the integration of systems and processes), and restructuring the combined company (which may include charges related to employees, assets and activities that will not continue in the combined company); and

In connection with our cost-reduction/productivity initiatives, we typically incur costs and charges associated with site closings and other facility rationalization actions, workforce reductions and the expansion of shared services, including the development of global systems.

All of our businesses and functions may be impacted by these actions, including sales and marketing, manufacturing and research and development (R&D), as well as groups such as information technology, shared services and corporate operations.

In early 2014, we announced that we would be incurring costs in 2014-2016 related to new programs: our new global commercial structure reorganization and additional cost-reduction/productivity initiatives.

We have the following initiatives underway:

Manufacturing plant network rationalization and optimization, where execution timelines are necessarily long. Our plant network strategy is expected to result in the exit of five sites over the next several years. In connection with these activities, during 2014-2016, we expect to incur costs of approximately $300 million associated with prior acquisition activity and costs of approximately $1.3 billion associated with new non-acquisition-related cost-reduction initiatives. Through June 28, 2015, we incurred approximately $252 million and $340 million, respectively, associated with these initiatives.

New global commercial structure reorganization, which primarily includes the streamlining of certain functions, the realignment of regional locations and colleagues to support the businesses, as well as implementing the necessary system changes to support future reporting requirements. In connection with this reorganization, during 2014-2016, we expect to incur costs of approximately $300 million. Through June 28, 2015, we incurred approximately $191 million associated with this reorganization.

Other new cost-reduction/productivity initiatives, primarily related to commercial property rationalization and consolidation. In connection with these cost-reduction activities, during 2014-2016, we expect to incur costs of approximately $900 million. Through June 28, 2015, we incurred approximately $263 million associated with these initiatives.

The costs expected to be incurred during 2014-2016, of approximately $2.8 billion in total, include restructuring charges, integration costs, implementation costs and additional depreciation asset restructuring. Of this amount, we expect that about a quarter of the charges will be non-cash.

Current-Period Key Activities

In the first six months of 2015, we incurred approximately $280 million in cost-reduction and acquisition-related costs (excluding transaction costs) in connection with the aforementioned programs, primarily associated with our manufacturing and sales operations.

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

The following table provides the components of costs associated with acquisitions and cost-reduction/productivity initiatives:

Three Months Ended

Six Months Ended

(MILLIONS OF DOLLARS)

June 28,

2015

June 29,

2014

June 28,

2015

June 29,

2014

Restructuring charges(a):

Employee terminations

34

17

65

47

Asset impairments

13

11

19

Exit costs

36

10

40

Total restructuring charges

43

66

85

106

Transaction costs(b)

Pre-integration/integration costs(c)

42

15

54

33

Restructuring charges and certain acquisition-related costs

86

81

146

139

Additional depreciation asset restructuring recorded in our condensed consolidated statements of income as follows(d):

Cost of sales

28

72

45

146

Selling, informational and administrative expenses

Research and development expenses

29

29

Total additional depreciation asset restructuring

28

102

47

176

Implementation costs recorded in our condensed consolidated statements of income as follows(e):

Cost of sales

28

22

41

28

Selling, informational and administrative expenses

13

38

39

53

Research and development expenses

16

12

27

Other (income)/deductions net

Total implementation costs

45

76

93

108

Total costs associated with acquisitions and cost-reduction/productivity initiatives

159

259

286

423

(a)

In the six months ended June 28, 2015, Employee terminations represent the expected reduction of the workforce by approximately 500 employees, mainly in sales.

The restructuring charges for 2015 are associated with the following:

For the second quarter of 2015, the Global Innovative Pharmaceutical segment (GIP) ($7 million); the Global Vaccines, Oncology and Consumer Healthcare segment (VOC) ($14 million); the Global Established Pharmaceutical segment (GEP) ($2 million income); Worldwide Research and Development and Medical (WRD/M) ($4 million); manufacturing operations ($14 million); and Corporate ($6 million).

For the first six months of 2015, GIP ($19 million); VOC ($27 million); GEP ($8 million); WRD/M ($16 million); manufacturing operations ($8 million income); and Corporate ($24 million).

The restructuring charges for 2014 are associated with the following:

For the second quarter of 2014, GIP ($9 million); VOC ($6 million); GEP ($24 million); WRD/M ($8 million); manufacturing operations ($12 million); and Corporate ($7 million).

For the first six months of 2014, GIP ($11 million); VOC ($6 million); GEP ($31 million); WRD/M ($9 million); manufacturing operations ($38 million); and Corporate ($11 million).

(b)

Transaction costs represent external costs directly related to acquired businesses and primarily include expenditures for banking, legal, accounting and other similar services.

(c)

Pre-integration costs represent external, incremental costs directly related to our pending acquisition with Hospira. Integration costs represent external, incremental costs directly related to integrating acquired businesses, and primarily include expenditures for consulting and the integration of systems and processes.

(d)

Additional depreciation asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.

(e)

Implementation costs represent external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.

10

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

The following table provides the components of and changes in our restructuring accruals:

(MILLIONS OF DOLLARS)

Employee

Termination

Costs

Asset

Impairment

Charges

Exit Costs

Accrual

Balance, December 31, 2014(a)

1,114

52

1,166

Provision

65

11

10

85

Utilization and other(b)

(197

(11

(36

(244

Balance, June 28, 2015(c)

982

26

1,008

(a)

Included in Other current liabilities ($735 million) and Other noncurrent liabilities ($431 million).

(b)

Includes adjustments for foreign currency translation.

(c)

Included in Other current liabilities ($575 million) and Other noncurrent liabilities ($433 million).

Note 4. Other (Income)/Deductions Net

The following table provides components of Other (income)/deductions net:

Three Months Ended

Six Months Ended

(MILLIONS OF DOLLARS)

June 28,

2015

June 29,